After years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.
Pooja Murthy, MD
Advertisement
Articles by Pooja Murthy, MD
Advertisement
Latest Updated Articles
Integrating PARP Inhibitors Into the Treatment of WomenDecember 30th 2018
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5